Alirocumab Reduces LDL Cholesterol in Patients With Homozygous Familial Hypercholesterolemia
March 31, 2020

By Alex Morrisson

WEST PALM BEACH, Fla -- March 31, 2020 - Alirocumab reduced low-density lipoprotein (LDL) cholesterol in patients with homozygous familial hypercholesterolemia, according to a study presented at the Virtual Meeting of the American College of Cardiology (ACC).

Findings from the ODYSSEY HoFH trial showed that alirocumab decreased LDL cholesterol by an average of 26.9% over 12 weeks compared with an increase of 8.6% among patients randomised to placebo (P

“The addition of alirocumab on top of maximally-tolerated lipid lowering therapy helps patients get closer to their LDL cholesterol goal,” said Dirk Blom, MD, University of Cape Town, Cape Town, South Africa.

Patients in the study were randomised to receive subcutaneous alirocumab 150 mg every 2 weeks (n = 45) or placebo (n = 24). Patients were diagnosed with homozygous familial hypercholesterolemia had baseline LDL cholesterol levels of 295 mg/dl and 259.6 mg/dl, respectively. All patients were on stable lipid-lowering therapy and/or apheresis.

After 4 weeks of treatment, patients on alirocumab had reduced their LDL cholesterol levels by about 30%, and then maintained that reduction through the 12-week period.

“LDL-cholesterol percent reduction with alirocumab is less pronounced in patients with homozygous familial hypercholesterolemia than in other forms of hypercholesterolemia as homozygous familial hypercholesterolemia is characterised by severely impaired LDL-receptor function,” Dr. Blom noted. Nevertheless, “substantial and significant absolute reductions in LDL cholesterol were observed with alirocumab.”

Funding for this study was provided by Sanofi and Regeneron.

[Presentation title: Alirocumab Efficacy and Safety in Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH). Abstract 20-LB-20345-ACC]